Stelara (Ustekinumab) 45mg/0.5mL SC Prefilled Syringe

$14,250.00

Drug Info: ApoThera Drug Disease Clinical Support App

Crohn Disease
Induction 
– ≤55 kg: 260 mg IV x 1 dose
– 55 kg to 85 kg: – 390 mg IV x 1 dose
– >85 kg: 520 mg IV x 1 dose
Maintenance Dose
– 90 mg SC every 8 weeks
– Begin maintenance dosing 8 weeks after the IV induction dose
Plaque Psoriasis
Dosing ≤100 kg
– 45 mg SC at 0 and 4 weeks
THEN,
– 45 mg SC every 12 weeks thereafter
Dosing >100 kg
– 90 mg SC at 0 and 4 weeks
THEN,
– 90 mg SC every 12 weeks thereafter
– Doses of 45 mg SC given to patients >100 kg were also efficacious; however, 90 mg is the recommended dose in these patients due to greater efficacy.
Psoriatic Arthritis
– Treatment of active psoriatic arthritis (as monotherapy or in combination with methotrexate) in adults
– When used for psoriatic arthritis, may be administered alone or in combination with methotrexate.
Initial Dose
– 45 mg at 0 and 4 weeks
Maintenance Dose
– 45 mg every 12 weeks thereafter.
Find a Physician:
NDC: 57894-0060-03 Categories: ,

1 Syringe = 1 Unit

Description

Drug Info: ApoThera Drug Disease Clinical Support App

SC Administration
– Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks
– Rotate sites
– Do not inject into tender, bruised, erythematous, or indurated skin
– Avoid areas of skin where psoriasis is present
– Discard any unused portion
– Intended for use under supervision of physician; self-injection may occur after proper training
 
Storage
– Refrigerate prefilled syringes at 2°C to 8°C (36°F to 46°F)
– Do not freeze
– Store vials upright
– Keep the product in the original carton to protect from light until the time of use.
– Do not shake.
– Discard any unused portion
Monitoring
– Tuberculosis screening (prior to initiating and periodically during therapy)
– CBC
– Ustekinumab-antibody formation
– Signs and symptoms of infection, reversible posterior leukoencephalopathy syndrome (RPLS), and squamous cell skin carcinoma